scholarly journals New Evidence of Significant Association between EBV Presence and Lymphoproliferative Disorders Susceptibility in Patients with Rheumatoid Arthritis: A Systematic Review with Meta-Analysis

Viruses ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 115
Author(s):  
Ana Banko ◽  
Danijela Miljanovic ◽  
Ivana Lazarevic ◽  
Ivica Jeremic ◽  
Aleksa Despotovic ◽  
...  

Development of lymphoproliferative disorders (LPDs) is one of the well-known life-threatening complications in rheumatoid arthritis (RA) patients. However, there is a lack of definitive conclusions regarding the role of Epstein-Barr virus (EBV) activity in RA initiation and progression, especially in promoting LPDs. A systematic review and meta-analysis of studies that reported an EBV positive result in RA-LPD patients and controls were conducted. Studies published before 27 July 2021 were identified through PubMed, Web of Science, and SCOPUS. A total of 79 articles were included in the systematic review. The prevalence of EBV positive result among RA-LPD patients was 54% (OR = 1.54, 95% CI = 1.45–1.64). There was a statistically significant association between EBV presence and LPD susceptibility in RA patients in comparison with all controls (OR = 1.88, 95% CI = 1.29–2.73) and in comparison with LPD patients only (OR = 1.92, 95% CI = 1.15–3.19). This association was not shown in comparison with patients with autoimmune diseases other than RA who developed LPD (OR = 0.79, 95% CI = 0.30–2.09). This meta-analysis confirmed a high prevalence of EBV in the RA-LPD population. Furthermore, it provides evidence for the association between EBV presence and LPD susceptibility in RA patients, but not in those with other autoimmune diseases who developed LPD.

2020 ◽  
Vol 9 (4) ◽  
pp. 3092-3100 ◽  
Author(s):  
Shivaranjhany Sivakumar ◽  
Archana A. Gupta ◽  
Nik Mohd Mazuan Nik Mohd Rosdy ◽  
Annapurny Venkiteswaran ◽  
A. Thirumal Raj ◽  
...  

2021 ◽  
Vol 65 (3) ◽  
pp. 276-286
Author(s):  
Tatyana V. Solomay ◽  
Tatyana A. Semenenko ◽  
Alexey I. Blokh

Introduction. Attempts to assess the prevalence of antibodies (seroprevalence) to the Epstein-Barr virus have been made several times. Still, a complete understanding of this issue has not been reached due to the small samples of the surveyed. The goal is to evaluate seroprevalence in different age groups in Europe and Asia using a systematic review and meta-analysis. Material and methods. The search for publications was carried out on PubMed, Cochrane Reviews/CochraneLibrary, eLibrary, Cyberleninka, Researchgate from May 6 to 30, 2020. A total of 2,364 articles were found, 12 of which were included in the study. Seroprevalence to Epstein-Barr virus was determined in 67,561 individuals aged 0 to 80 years. The research results were distributed by age groups, continents (Europe and Asia), and their implementation (2000-2012 and 2013-2019) and subjected to meta-analysis. Results. Minimal seroprevalence was detected among children under 1 and 1-2 years of age (53.3 and 50.9%). With increasing age, it grew, and people over 18 years of age were more than 90%. In 2013-2019, the index value (68.9%) was significantly higher than in 2000-2012 (89.6%). In Asian countries in 2000-2019, seroprevalence (86.7%) was considerably higher than in Europe (76.3%). The highest growth rate was observed in 7-14 years. In 2000-2012, the maximum growth rate of seroprevalence occurred in 15-17 years and 2013-2019 - 3-6 years. For all age groups, the growth rate was higher in Europe than in Asia and 2013-2019 compared to 2000-2012. Conclusion. The meta-analysis revealed differences in seroprevalence depending on age and territory of residence and the growth of indices in the trend.


Sign in / Sign up

Export Citation Format

Share Document